MA32602B1 - Utilisation de dronedarone pour la preparation d'un medicament pour la prevention d'un accident vasculaire cerebral ou un accident ischemique transitoire - Google Patents

Utilisation de dronedarone pour la preparation d'un medicament pour la prevention d'un accident vasculaire cerebral ou un accident ischemique transitoire

Info

Publication number
MA32602B1
MA32602B1 MA33659A MA33659A MA32602B1 MA 32602 B1 MA32602 B1 MA 32602B1 MA 33659 A MA33659 A MA 33659A MA 33659 A MA33659 A MA 33659A MA 32602 B1 MA32602 B1 MA 32602B1
Authority
MA
Morocco
Prior art keywords
drodenarone
drug
occurrence
prepare
prevent
Prior art date
Application number
MA33659A
Other languages
Arabic (ar)
English (en)
Inventor
Christophe Gaudin
Nacéra Hamdani
Davide Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40149599&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32602(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32602B1 publication Critical patent/MA32602B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention porte sur l'utilisation de la dronédarone pour la préparation d'un médicament pour la prévention d'un accident vasculaire cérébral ou d'un accident ischémique transitoire.
MA33659A 2008-08-07 2011-03-01 Utilisation de dronedarone pour la preparation d'un medicament pour la prevention d'un accident vasculaire cerebral ou un accident ischemique transitoire MA32602B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290761A EP2153830A1 (fr) 2008-08-07 2008-08-07 Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention des accidents vasculaires cérébraux ou des accidents ischémiques transitoires
US8780308P 2008-08-11 2008-08-11
PCT/IB2009/006831 WO2010015939A1 (fr) 2008-08-07 2009-08-03 Utilisation de la dronédarone pour la préparation d'un médicament pour la prévention d'un accident vasculaire cérébral ou d’un accident ischémique transitoire

Publications (1)

Publication Number Publication Date
MA32602B1 true MA32602B1 (fr) 2011-09-01

Family

ID=40149599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33659A MA32602B1 (fr) 2008-08-07 2011-03-01 Utilisation de dronedarone pour la preparation d'un medicament pour la prevention d'un accident vasculaire cerebral ou un accident ischemique transitoire

Country Status (24)

Country Link
US (1) US20110230552A1 (fr)
EP (2) EP2153830A1 (fr)
JP (1) JP2011529958A (fr)
KR (1) KR20110042344A (fr)
CN (1) CN102149377A (fr)
AR (1) AR073265A1 (fr)
AU (1) AU2009278864A1 (fr)
BR (1) BRPI0917569A2 (fr)
CA (1) CA2733149A1 (fr)
CL (1) CL2011000268A1 (fr)
CO (1) CO6351721A2 (fr)
CR (1) CR20110061A (fr)
DO (1) DOP2011000043A (fr)
EA (1) EA201170301A1 (fr)
EC (1) ECSP11010811A (fr)
IL (1) IL211098A0 (fr)
MA (1) MA32602B1 (fr)
MX (1) MX2011001461A (fr)
NI (1) NI201100034A (fr)
PE (1) PE20110706A1 (fr)
SV (1) SV2011003827A (fr)
TW (1) TW201010695A (fr)
UY (1) UY32040A (fr)
WO (1) WO2010015939A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518785A (ja) * 2008-04-17 2011-06-30 サノフイ−アベンテイス 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
AR081392A1 (es) * 2010-05-13 2012-08-29 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para la prevencion de hospitalizaciones cardiovasculares o muerte o sucesos cardiovasculares en pacientes con fibrilacion auricular permanente
EP2387997A1 (fr) * 2010-05-18 2011-11-23 Sanofi Utilisation de la dronédarone pour la préparation d'un médicament pour la prévention d'événements cardiovasculaires chez des patients souffrant de fibrillation auriculaire permanente tout au long de la période d'administration de la dronédarone
EP2387996A1 (fr) * 2010-05-17 2011-11-23 Sanofi Utilisation de la dronédarone pour la préparation d'un médicament destiné à la prévention d'événements cardiovasculaires chez des patients souffrant de fibrillation auriculaire permanente
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2013024411A1 (fr) 2011-08-12 2013-02-21 Lupin Limited Formulation cobroyée de dronédarone
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.

Also Published As

Publication number Publication date
ECSP11010811A (es) 2011-03-31
WO2010015939A1 (fr) 2010-02-11
IL211098A0 (en) 2011-04-28
CR20110061A (es) 2011-04-04
EP2326324A1 (fr) 2011-06-01
TW201010695A (en) 2010-03-16
CA2733149A1 (fr) 2010-02-11
NI201100034A (es) 2011-10-20
PE20110706A1 (es) 2011-10-11
EP2153830A1 (fr) 2010-02-17
EA201170301A1 (ru) 2012-01-30
BRPI0917569A2 (pt) 2019-09-24
MX2011001461A (es) 2011-03-29
AU2009278864A1 (en) 2010-02-11
KR20110042344A (ko) 2011-04-26
CO6351721A2 (es) 2011-12-20
AR073265A1 (es) 2010-10-28
JP2011529958A (ja) 2011-12-15
CN102149377A (zh) 2011-08-10
SV2011003827A (es) 2011-04-29
US20110230552A1 (en) 2011-09-22
CL2011000268A1 (es) 2011-07-29
DOP2011000043A (es) 2011-03-15
UY32040A (es) 2010-03-26

Similar Documents

Publication Publication Date Title
MA32602B1 (fr) Utilisation de dronedarone pour la preparation d'un medicament pour la prevention d'un accident vasculaire cerebral ou un accident ischemique transitoire
MA32462B1 (fr) Dronedarone dans le traitement prophylactique de la fibrillation auriculaire permanente
MA32354B1 (fr) UTILISATION DE DRONÉDARONE DANS UN MÉDICAMENT UTILISÉ POUR PRÉVENIR UN ÉPISODE CARDIOVASCULAIRE MENANT à L'HOSPITALISATION OU à LA MORT
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA33373B1 (fr) Composition pharmaceutique pour contraception d'urgence
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
MX356421B (es) Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA33220B1 (fr) Composition pharmaceutique a proprietes anti-inflammatoires
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
WO2012075362A3 (fr) Modulateurs du récepteur cxcr4 de la chimiokine et leurs utilisations
FR2959416B1 (fr) Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
FR2917292B1 (fr) Utilisation d'une hemoglobine pour la preparation de pansements, et pansements ainsi prepares
CL2007002106A1 (es) COMPOSICION MONOFASICA LIQUIDA QUE COMPRENDE 3 ANTIOXIDANTES, 1o, COMPUESTO FENOLICO SINTETICO QUE NO ES DERIVADO DE QUINOOLINA, 2o, ACIDOS FENOLICO, ASCORBICO, TOCOFEROLES, LECITINA, BIOFLAVONOIDE O TERPENOIDE Y 3o, COMPUESTO DERIVADO DE QUINOLINA;
FR2921795B1 (fr) Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
EP2420230A3 (fr) Agents anti-angiogéniques
MA31798B1 (fr) Composés organiques
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
FR2930150B1 (fr) Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
MX2010001243A (es) Composicion anti-inflamatoria.
IT1400989B1 (it) Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
FR3069775B1 (fr) 1,4 :3,6 dianhydrohexitols pour hydrater la peau
WO2010149794A3 (fr) Nouvelle composition pharmaceutique comprenant du poly(allylamine-co-n,n'-diallyl-1,3-diamino-2-hydroxypropane)
MA31930B1 (fr) Utilisation de la méquitazine sous la forme de racémate ou d'énantiomères pour la préparation d'un médicament destiné au traitement ou à la prévention de pathologies impliquant les récepteurs histaminiques h4